NFL Biosciences Wins French Approval for Phase 2 Smoking Cessation Trial

• NFL Biosciences secured French regulatory approvals to begin its Phase 2 TONIC trial of NFL-102 for smoking and nicotine cessation.
• The 310-participant trial will begin enrollment in November 2026; Part A results are scheduled for April 2027.
• Current cash covers Part A; the company is seeking strategic and financial partners to fund Part B.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NFL Biosciences SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021927272) on October 22, 2026, and is solely responsible for the information contained therein.